Switching from an Injection to a GLP-1 Tablet

You can switch from a weekly GLP-1 injection to a daily tablet, but only through a prescriber, and the right choice depends on which injection you are on and why you want to change. In 2026 the MHRA authorised two tablets for weight management: Wegovy tablets (oral semaglutide) in June and Foundayo (orforglipron) in August. Average weight loss with the tablets is broadly similar to Wegovy injections but lower than with Mounjaro. There is no do-it-yourself dose conversion. This guide covers the evidence, the practical differences and how prescribers approach the change.

Why people want to switch to a tablet

For many people, weekly injections are straightforward once they get used to them. But there are several reasons people ask about tablets:

• Needle aversion. Some people never become comfortable injecting.
• Travel and storage. Injections need refrigeration before first use (and the in-use rules vary by product). Tablets are generally easier to carry. Our guide to Mounjaro storage and travel explains the injection rules.
• Preference for a daily routine. Some people find a daily habit easier to remember than a weekly one.
• Injection-site reactions. A minority of people have persistent redness, itching or lumps at injection sites.
• Cost or availability. Tablet pricing and availability may differ from injections, depending on the provider. See our prices page for current comparisons; we don't quote prices in guides.
• Maintenance. Some people want a different option once they reach a stable weight.

It is equally important to understand the trade-offs: a daily tablet means 365 doses a year rather than 52, and oral semaglutide in particular comes with strict instructions about food and water.

The GLP-1 tablets available in the UK

Wegovy tablets (oral semaglutide)

The MHRA authorised Wegovy tablets for weight management on 11 June 2026. They contain semaglutide, the same active ingredient as Wegovy injections, in a tablet formulated with an absorption enhancer. The licence covers adults with a BMI of 30 or more, or a BMI of 27 to 30 with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

As reported at approval, treatment starts at a low daily dose and is increased in steps, with at least a month at each step, up to a maintenance dose of 25 mg. Check the current SmPC for the definitive schedule.

Note that Rybelsus, another oral semaglutide product, is licensed only for type 2 diabetes in the UK, not for weight management. The two are not interchangeable. See our guide to Rybelsus and weight loss.

Foundayo (orforglipron)

The MHRA authorised orforglipron, branded Foundayo, on 10 August 2026, making the UK the first country in Europe to do so. It is licensed for weight management in adults with the same BMI criteria as above, and separately for type 2 diabetes. Orforglipron is a small-molecule (non-peptide) GLP-1 receptor agonist, which means it is absorbed differently from semaglutide. The MHRA's announcement states it can be taken at any time of day with no food or water restrictions. Treatment starts at a low dose and is increased in monthly steps.

For more, see our guides to oral semaglutide and Foundayo/orforglipron, and the oral GLP-1 hub.

How tablets compare with injections

The table below summarises the main trials. They were separate trials with different populations and designs, so figures are not perfectly comparable. Treat them as a guide to the general picture rather than a precise ranking.

A few points stand out:

• Oral semaglutide 25 mg and Wegovy 2.4 mg injection produce broadly similar average weight loss. The tablet is more accurately described as an alternative way of taking semaglutide rather than a stronger or weaker version.
• Both tablets produce less average weight loss than tirzepatide. If you are doing well on Mounjaro, switching to a tablet may mean slower progress or some regain.
• Individual responses vary widely. Averages hide a broad range in every trial.

Our full comparison is in oral vs injectable GLP-1 medicines, with direct comparisons at Mounjaro vs oral semaglutide and Wegovy vs oral semaglutide.

What happens to weight after switching: the evidence

The most directly relevant evidence comes from the ATTAIN-MAINTAIN trial of orforglipron. People who had been treated with injectable tirzepatide or semaglutide for 72 weeks in the SURMOUNT-5 trial were randomly assigned to switch to orforglipron or to placebo for 52 weeks. As reported in late 2025:

In plain terms, switching to a tablet helped many people hold on to most of their weight loss, and did much better than stopping treatment, but on average they did not keep all of it. People coming from tirzepatide, which is the more potent injection on average, saw a smaller advantage over placebo.

For oral semaglutide, the active ingredient is the same as Wegovy injection. At the time of approval it was reported that the UK prescribing information includes guidance for prescribers on transferring people from the injection to the tablet. This is a matter for your prescriber, not something to work out from news reports.

Practical differences you'll notice

Taking oral semaglutide correctly

Semaglutide is a peptide, and peptides are normally broken down in the gut. The tablet uses an absorption enhancer that works only under specific conditions. That is why the patient leaflet gives strict instructions, which typically include:

• Taking the tablet on an empty stomach, usually first thing in the morning
• Swallowing it whole with only a small sip of plain water
• Waiting a set time (at least 30 minutes for Rybelsus) before eating, drinking anything else or taking other oral medicines

If these instructions are not followed, much less semaglutide may be absorbed and the medicine may work less well. Read the leaflet for your specific product and ask your pharmacist if anything is unclear.

Taking orforglipron

Orforglipron's small-molecule design means it is absorbed without the same restrictions. According to the MHRA, it can be taken at any time of day without food or water restrictions. For many people, this is a practical advantage, particularly if they take other morning medicines.

Daily versus weekly

A daily routine suits some people better than others. Missing a daily dose is more likely than missing a weekly one simply because there are more doses. The leaflet will explain what to do if you miss a dose, and your prescriber can advise.

Other medicines

Oral semaglutide's timing rules can affect when you take other morning tablets, such as levothyroxine. Like all GLP-1 medicines, both tablets slow stomach emptying, which can affect the absorption of some other oral medicines. Tell your prescriber and pharmacist about everything you take. Our guide to GLP-1 medication interactions explains the main issues.

Side effects

The side effects of GLP-1 tablets are broadly similar to injections: nausea, diarrhoea, constipation, vomiting, indigestion and reduced appetite are the most common, and are most likely after starting or increasing a dose. Injection-site reactions obviously no longer apply. See our guide to oral GLP-1 side effects.

How prescribers approach the switch

The following describes general considerations, not instructions. Changing medicine, formulation or dose must be done with your prescriber.

Assessing whether a switch makes sense

Your prescriber will usually want to know:

• Which injection and dose you are on, and for how long
• How much weight you have lost and whether it is still changing
• Your reasons for wanting a tablet
• Your side-effect history
• Your other medicines, including any taken first thing in the morning
• Whether you can reliably follow a daily routine and, for oral semaglutide, its timing rules
• Whether you have any condition that makes a particular tablet unsuitable

They will also re-check eligibility and cautions. For example, all of these medicines are unsuitable during pregnancy, and contraception advice may need reviewing.

Choosing the tablet and starting dose

There is no simple milligram equivalence between injections and tablets, because absorption differs so much. Depending on the tablet and your history, the prescriber may follow guidance in the SmPC for transferring from an injection, or may start at a lower dose and increase step by step to limit side effects. The decision weighs the risk of weaker appetite control against the risk of gastrointestinal side effects.

Timing

Prescribers generally plan the change so you are not left with a long gap or an overlap. Because your last weekly injection continues to act for some days, the timing of the first tablet matters and should follow your prescriber's instructions.

Monitoring after the switch

Expect a review within the first few weeks and before any dose increase. Report any significant change in weight, appetite or side effects. If weight starts to rise noticeably, your prescriber can review the dose or consider returning to an injection.

Is a tablet right for you?

These questions may help you prepare for a conversation with your prescriber:

You can compare the providers that offer tablet treatments on our providers page.

If you are considering a different injection rather than a tablet, see our guides to switching from Mounjaro to Wegovy and switching providers mid-treatment. For a broad overview, our UK guide to oral GLP-1 medicines is a good place to start.

Common questions about tablet routines

What if I take other tablets in the morning?

This matters most for oral semaglutide, because of its empty-stomach and waiting-time rules. If you take medicines such as levothyroxine, blood pressure tablets or others first thing, you and your pharmacist will need to agree a routine that respects the timing instructions for each one. Never change the timing of an existing medicine without advice. Orforglipron's lack of food and water restrictions can make it simpler to fit alongside other morning medicines, but interactions still need checking.

What happens if I'm sick shortly after taking a tablet?

Vomiting soon after taking any oral medicine can mean less of it is absorbed. The patient leaflet will explain what to do; in general, don't take an extra tablet without advice. If vomiting is persistent, contact your prescriber, as it may also lead to dehydration.

Can I split or crush the tablets?

Oral semaglutide tablets should be swallowed whole, because crushing or splitting them can interfere with how the absorption enhancer works. Check the patient leaflet for each product and ask your pharmacist if you have difficulty swallowing tablets.

Will a tablet travel more easily than my pen?

Generally, yes. Tablets don't need refrigeration in the way unopened injection pens do, which can make travel and storage simpler. Keep them in their original packaging, follow the storage instructions in the leaflet, and carry a copy of your prescription when travelling abroad.

Weighing the trade-offs

It can help to set out the pros and cons in one place. The balance will differ from person to person.

Thinking through how each factor applies to your daily life can make the conversation with your prescriber more focused. Some people try a tablet and decide to return to injections; others find a tablet suits them better. Both are reasonable outcomes, as long as changes are made with your prescriber.

A note on cost

The cost of tablet treatment depends on the product, the dose and the provider, and pricing for newly licensed medicines may change as more providers offer them. Remember that the cost of a daily tablet over a month should be compared with the cost of four weekly injections, and that consultation, follow-up and delivery charges vary between services. We don't quote prices in our guides, but our prices page compares current options, and our guide to how weight-loss injection pricing works explains the factors that affect cost.

For related guides, see our switching topic hub.

When to speak to a professional

Talk to your prescriber before making any change, and contact them promptly if:

• You want to move from an injection to a tablet, or back again
• You are unsure how to take your tablet correctly
• You have missed several doses
• Your weight is rising after the switch
• Side effects are making it hard to eat or drink
• You start a new medicine, especially one taken in the morning or for diabetes
• You become pregnant or are planning pregnancy

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, sometimes spreading to the back, with or without vomiting (a possible sign of pancreatitis)
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes
• Persistent vomiting or diarrhoea with signs of dehydration
• Signs of a severe allergic reaction, such as swelling of the face, lips or throat, or difficulty breathing
• Sudden changes in vision

Report suspected side effects through the MHRA Yellow Card scheme.